Apexigen America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 27
- Market Cap
- -
- Website
- http://www.apexigen.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
- Conditions
- CancerCancer of SkinMelanomaUnresectable MelanomaMetastatic MelanomaMelanoma (Skin)
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04337931
- Locations
- 🇵🇱
Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan, Poland
🇵🇱Centrum Onkologii - Instytutu im. Marii Skłodowskiej - Curie w Warszawie, Warsaw, Poland
🇪🇸Hospital Universitario San Juan De Alicante, Alicante, Spain
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
- Conditions
- Esophageal CancerGastroEsophageal Cancer
- Interventions
- Radiation: Radiation TherapyProcedure: Surgical resection of tumor
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03165994
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
- Conditions
- Metastatic MelanomaNon Small Cell Lung Cancer MetastaticMelanomaCancerNeoplasm of Lung
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT03123783
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Study of the CD40 Agonistic Monoclonal Antibody APX005M
- Conditions
- CancerUrothelial CarcinomaHead and Neck CancerNSCLCMSI-HMelanoma
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02482168
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States